EPSRC logo

Details of Grant 

EPSRC Reference: EP/L01646X/1
Title: EPSRC Centre for Doctoral Training in Advanced Therapeutics & Nanomedicines
Principal Investigator: Stolnik-Trenkic, Professor SS
Other Investigators:
Shakesheff, Professor K Alexander, Professor C Marlow, Dr M E
Gaisford, Professor S Brocchini, Professor SJ
Researcher Co-Investigators:
Project Partners:
AstraZeneca Boots UK Ltd GlaxoSmithKline plc (GSK)
Kuecept Ltd Merck Sharpe and Dohme Ltd (MSD) Novartis
Pfizer Syngenta UCB
Department: Sch of Pharmacy
Organisation: University of Nottingham
Scheme: Centre for Doctoral Training
Starts: 01 May 2014 Ends: 30 June 2023 Value (£): 4,667,466
EPSRC Research Topic Classifications:
Drug Formulation & Delivery
EPSRC Industrial Sector Classifications:
Healthcare Pharmaceuticals and Biotechnology
Related Grants:
Panel History:
Panel DatePanel NameOutcome
23 Oct 2013 EPSRC CDT 2013 Interviews Panel H Announced
Summary on Grant Application Form
At the forefront of global pharmaceutical research is the development of "intelligent" medicines which are effective,

affordable and safe, for diseases that are poorly treated (for example, cancer, infections, cardiovascular disease and

neurodegeneration). The ideal medicine could be taken by a variety of means (pill, injection or inhaler), but should only act

on diseased tissue at a 'specific' site in the body. However, the ability to direct a drug to particular desired locations in the

body is still a major scientific challenge. Drugs can easily be degraded en route to their target leading to quickly decreasing

drug levels. Higher levels of medication do not circumvent this problem due to potentially increased side effects or toxicity.

Some drugs can simply not be delivered to their target due to barriers within the body: the ability to reach specific disease

sites while leaving healthy cells intact would mean not only better therapeutic outcomes, but better qualities of life for

patients and carers. Benefits through better formulation and targeting will be very apparent for those diseases that are

increasing in ageing populations, such as cancer, which is predicted to affect (directly or indirectly) 1 in 3 in the European

population by 2020. For these and other devastating diseases new therapeutic regimens are urgently needed.

Research into Advanced Therapeutics requires not just scientific innovation but also a changed training paradigm for the

scientists involved. Many advanced therapeutic formulations are inherently in the 'nano' size range i.e. larger than

conventional drugs such as ibuprofen and paracetamol, but smaller than human cells, and thus spanning the traditional

domains of chemistry, biology and medicine. Developing the science of these emergent nanomedicines towards clinical

products requires a new generation of researchers trained across multiple scientific disciplines. The Centre for Doctoral

Training we propose builds on our existing close partnerships with leading industry and academic institutions world-wide to

offer training in the diverse and challenging disciplines underlying pharmaceutical science. The proposed Centre will

combine expertise in analytical and medicinal chemistry, with materials science, engineering, biology and industrial

pharmaceutics, to equip researchers with the skills they need to develop the next generation of pharmaceutical products.

Accordingly, the CDT offers wider benefits to society as researchers trained in the Centre will be attractive to the

chemicals, engineering and materials sectors as well as healthcare and medicine. Within the proposed CDT we aim to

continue our broad-based training approach, such that researchers will have innovation and entrepreneurial skills, so vital

for the developing industry sector. This focus on translational and business skills helped a team from Nottingham in the

existing CDT to be winners of the NanoCom business competition in 2012.

Ultimately, improvements in the industry and practice of therapeutics combined with enhanced academy / industry

pathways to translation offer many future advantages, not just to the science, industry and medical base, but to patients,

carers and society as a whole.
Key Findings
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Potential use in non-academic contexts
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Description This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Date Materialised
Sectors submitted by the Researcher
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Project URL:  
Further Information:  
Organisation Website: http://www.nottingham.ac.uk